FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1971014183> ?p ?o ?g. }

• W1971014183 endingPage "605" @default.
• W1971014183 startingPage "594" @default.
• W1971014183 abstract "Mycophenolic acid (MPA) is an inosine monophosphate dehydrogenase inhibitor used for glomerulonephritis treatment. The objective of the current study was to develop a population pharmacokinetic model for MPA and metabolites in glomerulonephritis to enable appropriate design of MPA regimens in these patients with alterations in kidney structure and function. Thirty-nine patients with glomerulonephritis and receiving mycophenolate mofetil were recruited to participate in a 24-hour pharmacokinetic study. Blood was collected at times 0, 0.5, 1.0, 1.5, 2, 3, 4, 6, 8, 12, and 24 hours and urine was collected over the intervals of 0 to 6, 6 to 12, and 12 to 24 hours. Plasma and urine samples were assayed for MPA and MPA glucuronide (MPAG) by high-performance liquid chromatography and for acyl-MPA glucuronide (AcMPAG) by liquid chromatography/mass spectrometry. Population pharmacokinetic analysis and covariate model building were evaluated using Non-linear Mixed Effect Modeling software (NONMEM, Version 6.2.0; ICON Development Solutions, Ellicott City, MD). The final model for MPA and its metabolites consisted of nine discrete compartments; 1) depot gastrointestinal; 2) central MPA; 3) peripheral MPA; 4) gallbladder; 5) MPA urine; 6) MPAG central; 7) MPAG urine; 8) AcMPAG central; and 9) AcMPAG urine compartment. The MPA population mean estimates for apparent nonrenal clearance (ClNR/F) and apparent central volume of distribution were 14.3 L/hr and 21.1 L, respectively. The mean population estimate for apparent renal clearance (ClR/F) was dependent on estimated creatinine clearances (eClcr); 0.0975 L/hr for eClcr 80 mL/min or less and 0.157 L/hr for eClcr greater than 80 mL/min. Covariate analyses identified: eClcr on CLNR,MPA/F (P < 0.001), eClcr (with a cutoff value at 80 mL/min) on CLR,MPA/F (P < 0.025), serum albumin on CLNR,MPA/F (P < 0.01), eClcr on CLR,MPAG/F (P < 0.001), and eClcr on CLR,AcMPAG/F (P < 0.001). Evaluation of the final model by visual predictive check showed that most of the observed values were within the 95th percent prediction interval generated from 100 simulations of the final model. The current population pharmacokinetic model demonstrated eClcr and serum albumin influenced the renal and nonrenal components of Cl/F, suggesting patients with glomerulonephritis would have highly altered MPA exposures." @default.
• W1971014183 created "2016-06-24" @default.
• W1971014183 creator A5002088781 @default.
• W1971014183 creator A5045125159 @default.
• W1971014183 date "2010-10-01" @default.
• W1971014183 modified "2023-09-25" @default.
• W1971014183 title "Population Pharmacokinetics of Mycophenolic Acid and Metabolites in Patients With Glomerulonephritis" @default.
• W1971014183 cites W1496085216 @default.
• W1971014183 cites W1550111394 @default.
• W1971014183 cites W1598969666 @default.
• W1971014183 cites W1955028047 @default.
• W1971014183 cites W1973334335 @default.
• W1971014183 cites W1977126062 @default.
• W1971014183 cites W1993063721 @default.
• W1971014183 cites W1994092210 @default.
• W1971014183 cites W1994502792 @default.
• W1971014183 cites W1995139644 @default.
• W1971014183 cites W1996853835 @default.
• W1971014183 cites W2000951272 @default.
• W1971014183 cites W2003143162 @default.
• W1971014183 cites W2004194066 @default.
• W1971014183 cites W2005953407 @default.
• W1971014183 cites W2024252223 @default.
• W1971014183 cites W2025501899 @default.
• W1971014183 cites W2028755482 @default.
• W1971014183 cites W2036959351 @default.
• W1971014183 cites W2056054156 @default.
• W1971014183 cites W2058839075 @default.
• W1971014183 cites W2066128566 @default.
• W1971014183 cites W2074416812 @default.
• W1971014183 cites W2078423532 @default.
• W1971014183 cites W2094074845 @default.
• W1971014183 cites W2096363861 @default.
• W1971014183 cites W2101399909 @default.
• W1971014183 cites W2102454572 @default.
• W1971014183 cites W2129352911 @default.
• W1971014183 cites W2160388191 @default.
• W1971014183 cites W2171121999 @default.
• W1971014183 cites W2409639874 @default.
• W1971014183 cites W3156996711 @default.
• W1971014183 doi "https://doi.org/10.1097/ftd.0b013e3181ee52e2" @default.
• W1971014183 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2944917" @default.
• W1971014183 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20736896" @default.
• W1971014183 hasPublicationYear "2010" @default.
• W1971014183 type Work @default.
• W1971014183 sameAs 1971014183 @default.
• W1971014183 citedByCount "20" @default.
• W1971014183 countsByYear W19710141832012 @default.
• W1971014183 countsByYear W19710141832013 @default.
• W1971014183 countsByYear W19710141832014 @default.
• W1971014183 countsByYear W19710141832017 @default.
• W1971014183 countsByYear W19710141832018 @default.
• W1971014183 countsByYear W19710141832020 @default.
• W1971014183 countsByYear W19710141832021 @default.
• W1971014183 countsByYear W19710141832023 @default.
• W1971014183 crossrefType "journal-article" @default.
• W1971014183 hasAuthorship W1971014183A5002088781 @default.
• W1971014183 hasAuthorship W1971014183A5045125159 @default.
• W1971014183 hasBestOaLocation W19710141832 @default.
• W1971014183 hasConcept C112705442 @default.
• W1971014183 hasConcept C126322002 @default.
• W1971014183 hasConcept C126894567 @default.
• W1971014183 hasConcept C139254425 @default.
• W1971014183 hasConcept C159641895 @default.
• W1971014183 hasConcept C181199279 @default.
• W1971014183 hasConcept C185592680 @default.
• W1971014183 hasConcept C2776239304 @default.
• W1971014183 hasConcept C2778033501 @default.
• W1971014183 hasConcept C2779186261 @default.
• W1971014183 hasConcept C2779907587 @default.
• W1971014183 hasConcept C2780026642 @default.
• W1971014183 hasConcept C2780306776 @default.
• W1971014183 hasConcept C2908647359 @default.
• W1971014183 hasConcept C2909935303 @default.
• W1971014183 hasConcept C2911091166 @default.
• W1971014183 hasConcept C55493867 @default.
• W1971014183 hasConcept C71924100 @default.
• W1971014183 hasConcept C87644729 @default.
• W1971014183 hasConcept C98274493 @default.
• W1971014183 hasConcept C99454951 @default.
• W1971014183 hasConceptScore W1971014183C112705442 @default.
• W1971014183 hasConceptScore W1971014183C126322002 @default.
• W1971014183 hasConceptScore W1971014183C126894567 @default.
• W1971014183 hasConceptScore W1971014183C139254425 @default.
• W1971014183 hasConceptScore W1971014183C159641895 @default.
• W1971014183 hasConceptScore W1971014183C181199279 @default.
• W1971014183 hasConceptScore W1971014183C185592680 @default.
• W1971014183 hasConceptScore W1971014183C2776239304 @default.
• W1971014183 hasConceptScore W1971014183C2778033501 @default.
• W1971014183 hasConceptScore W1971014183C2779186261 @default.
• W1971014183 hasConceptScore W1971014183C2779907587 @default.
• W1971014183 hasConceptScore W1971014183C2780026642 @default.
• W1971014183 hasConceptScore W1971014183C2780306776 @default.
• W1971014183 hasConceptScore W1971014183C2908647359 @default.
• W1971014183 hasConceptScore W1971014183C2909935303 @default.
• W1971014183 hasConceptScore W1971014183C2911091166 @default.
• W1971014183 hasConceptScore W1971014183C55493867 @default.
• W1971014183 hasConceptScore W1971014183C71924100 @default.

• next